Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | NEO212 |
| Trade Name | |
| Synonyms | |
| Drug Descriptions |
NEO212 is a conjugate of temozolomide and perillyl alcohol, which may result in decreased cell migration and invasion, inhibition of Fak/Src signaling, and cytotoxicity (PMID: 29440289, PMID: 31839810). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 | Bevacizumab Fluorouracil Irinotecan Leucovorin NEO212 | 0 | 1 |
| Carboplatin + NEO212 + Paclitaxel | Carboplatin NEO212 Paclitaxel | 0 | 1 |
| Ipilimumab + NEO212 | Ipilimumab NEO212 | 0 | 1 |
| NEO212 | NEO212 | 0 | 1 |
| NEO212 + Nivolumab | NEO212 Nivolumab | 0 | 1 |
| NEO212 + Pembrolizumab | NEO212 Pembrolizumab | 0 | 1 |
| NEO212 + Regorafenib | NEO212 Regorafenib | 0 | 1 |